追踪水母的签名:揭开原血栓状态的故事
Arul Rajamurugan Ps1, Arockiaraj Barnabas1, Sabarinath M1
1Institute of Rheumatology, Madras Medical College, Chennai, Tamil Nadu, India.
概括
初级抗脂综合征可能会导致罕见的血管问题,如下静脉血栓和心脏质量. 早期诊断和抗凝剂对于管理这些高凝血状态和预防栓塞事件至关重要.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 类风湿病学 类风湿病学
背景情况:
- 存在复杂的血管表现的高凝血状态,包括罕见的下腔静脉 (IVC) 血栓和心内质量.
- 这些情况往往导致诊断延迟和不良结果.
研究的目的:
- 描述一次性抗脂综合征的病例,呈现出IVC血栓形成和利布曼-萨克斯内心炎.
- 突出全面评估和早期检测在患有复发性血栓事件的患者的重要性.
主要方法:
- 一个30岁的女性病例报告,临床状况逐渐恶化.
- 诊断评估包括深静脉血栓,肝脏IVC血栓和心内质量的成像.
- 血清检测证实了原发性抗脂综合征.
主要成果:
- 患者出现了右腿胀,贫血和血小板狭窄症.
- 确定了肝脏IVC血栓形成,并带有附带循环和一个中枢质量 (利布曼-萨克斯内心炎).
- 初级抗脂综合征的诊断通过血清学测试得到证实.
结论:
- 主要抗脂综合征可以表现为罕见的血管和心脏并发症.
- 对患有复发性血栓事件的患者进行全面评估至关重要.
- 早期检测和持续的抗凝治疗对于减轻栓塞风险和改善结果至关重要.
相关概念视频
Venous Thrombosis III: Interprofessional Care
25
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
25
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
41
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
41
Anticoagulant Drugs: Low-Molecular-Weight Heparins
917
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
917
Venous Thrombosis I: Introduction
43
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
43
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K


